Is there still a room for crizotinib in first-line setting in ALK-positive NSCLC patients?

7 / 39

2nd G ALK TKI: PFS vs. treatment duration
HR=0.43; P<0.001
HR=0.49; P<0.001
Alectinib (ALEX)
Brigatinib
Crizotinib
PFS Alectinib 25.7 mo*.
Duration of treatment 17.9 mo.
Discontinuation 13% vs. 13%
PFS Crizotinib 11.1 mo.
Duration of treatment 10.7 mo.
*Updated 34.8 mo.
PFS Brigatinib NR.
Duration of treatment 9.2 mo.
Discontinuation 12% vs. 9%
PFS Crizotinib 9.8 mo.
Duration of treatment 7.4 mo.
Peters- NEJM 2017 * Camidge – ASCO 2018 * Camidge – NEJM 2018 * Popat –ESMO 2018
Brigatinib (ALTA-1L)
PFS w/o BM: 34.8 vs. 14.7
PFS w/o BM: HR 0.72 (0.44-1.18), P=0.2